RBFOX3 and hematoma: 1400 W (20 mg/kg) administered twice daily significantly suppressed the decrease of NeuN-positive cells in the center of hematoma (Fig. 7a,b) and the increase of Iba1-positive activated microglia/macrophages in the peri-hematoma region (Fig. 7c,d) at 72 h after induction of ICH.